GlassScriptPhysician profile
Prem Sahasranam
NPI 1720270820
$9,685.20
in general payments reported to CMS, 2019-2025
39 companies · $1,271 in 2025
The $1,271 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,567 · 2020: $991 · 2021: $1,806 · 2022: $1,989 · 2023: $1,253 · 2024: $809 · 2025: $1,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,217 · Long Term Medical Supply Or Device Loan: $74.97 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,217.08 |
| Long Term Medical Supply Or Device Loan | $74.97 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,020.75 | 2019-2025 | Tepezza, Repatha, Evenity |
| Novo Nordisk INC | $1,238.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $815.75 | 2019-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $777.28 | 2019-2023 | Farxiga |
| Abbvie INC. | $621.72 | 2019-2025 | Ubrelvy |
| Esperion Therapeutics, INC. | $466.31 | 2021-2023 | Nexletol |
| Abbott Laboratories | $399.60 | 2019-2025 | Freestyle Copilot, Freestyle Libre 3, Freestyle Insulinx |
| Insulet Corporation | $312.17 | 2019-2023 | Omnipod |
| Dexcom, INC. | $292.79 | 2019-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $270.75 | 2019-2024 | Jardiance, Trulicity, Mounjaro |
| Xeris Pharmaceuticals, INC. | $266.48 | 2022-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.92 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $207.00 | 2019-2024 | |
| Radius Health, INC. | $176.71 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $160.49 | 2023-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prem Sahasranam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.